Spelling suggestions: "subject:"fremdes"" "subject:"remdamiesi""
1 |
Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysisPiscoya, Alejandro, Ng-Sueng, Luis F., del Riego, Angela Parra, Cerna-Viacava, Renato, Pasupuleti, Vinay, Roman, Yuani M., Thota, Priyaleela, White, C. Michael, Hernandez, Adrian V. 01 December 2020 (has links)
Background Efficacy and safety of treatments for hospitalized COVID-19 are uncertain. We systematically reviewed efficacy and safety of remdesivir for the treatment of COVID-19. Methods Studies evaluating remdesivir in adults with hospitalized COVID-19 were searched in several engines until August 21, 2020. Primary outcomes included all-cause mortality, clinical improvement or recovery, need for invasive ventilation, and serious adverse events (SAEs). Inverse variance random effects meta-analyses were performed. Results We included four randomized controlled trials (RCTs) (n = 2296) [two vs. placebo (n = 1299) and two comparing 5-day vs. 10-day regimens (n = 997)], and two case series (n = 88). Studies used intravenous remdesivir 200mg the first day and 100mg for four or nine more days. One RCT (n = 236) was stopped early due to AEs; the other three RCTs reported outcomes between 11 and 15 days. Time to recovery was decreased by 4 days with remdesivir vs. placebo in one RCT (n = 1063), and by 0.8 days with 5-days vs. 10-days of therapy in another RCT (n = 397). Clinical improvement was better for 5-days regimen vs. standard of care in one RCT (n = 600). Remdesivir did not decrease all-cause mortality (RR 0.71, 95% CI 0.39 to 1.28, I2 = 43%) and need for invasive ventilation (RR 0.57, 95%CI 0.23 to 1.42, I2 = 60%) vs. placebo at 14 days but had fewer SAEs; 5-day decreased need for invasive ventilation and SAEs vs. 10-day in one RCT (n = 397). No differences in all-cause mortality or SAEs were seen among 5-day, 10-day and standard of care. There were some concerns of bias to high risk of bias in RCTs. Heterogeneity between studies could be due to different severities of disease, days of therapy before outcome determination, and how ordinal data was analyzed. Conclusions There is paucity of adequately powered and fully reported RCTs evaluating effects of remdesivir in hospitalized COVID-19 patients. Until stronger evidence emerges, we cannot conclude that remdesivir is efficacious for treating COVID-19. / Revisión por pares
|
2 |
SARS CoV-2 (COVID-19) Current Pharmacotherapy for Mother and InfantThigpen, Jim 01 January 2021 (has links)
The novel coronavirus disease 2019 (COVID-19), appeared in the United States over 1 year ago. This virus has a wide range of presentations, from being asymptomatic to causing severe acute respiratory syndrome, which can lead to death. It has led to a worldwide effort to find effective treatments, from repurposed medications to new discoveries, as well as the push to develop effective vaccines. As the race to fight this pandemic unfolds, this column provides what is currently available to combat this virus, how it has been utilized in the pregnant population, and what data have been made available about how these treatments affect fetal development and the neonate.
|
3 |
Effects of the RNA-Polymerase Inhibitors Remdesivir and Favipiravir on the Structure of Lipid Bilayers—An MD StudyBringas, Mauro, Luck, Meike, Müller, Peter, Scheidt, Holger A., Di Lella, Santiago 06 March 2024 (has links)
The structure and dynamics of membranes are crucial to ensure the proper functioning
of cells. There are some compounds used in therapeutics that show nonspecific interactions with
membranes in addition to their specific molecular target. Among them, two compounds recently
used in therapeutics against COVID-19, remdesivir and favipiravir, were subjected to molecular
dynamics simulation assays. In these, we demonstrated that the compounds can spontaneously
bind to model lipid membranes in the presence or absence of cholesterol. These findings correlate
with the corresponding experimental results recently reported by our group. In conclusion, insertion
of the compounds into the membrane is observed, with a mean position close to the phospholipid head groups.
|
Page generated in 0.0238 seconds